GSK plc (BVMF:G1SK34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 542.10B +22.1% |
| Revenue (ttm) | 225.81B +4.0% |
| Net Income | 40.15B +84.9% |
| EPS | 9.78 +86.6% |
| Shares Out | n/a |
| PE Ratio | 13.50 |
| Forward PE | 11.07 |
| Dividend | 1.66 (3.07%) |
| Ex-Dividend Date | May 14, 2026 |
| Volume | 20 |
| Open | 54.05 |
| Previous Close | n/a |
| Day's Range | 54.05 - 54.05 |
| 52-Week Range | 39.98 - 63.24 |
| Beta | 0.29 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 28, 2026 |
About GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It a... [Read more]
Financial Performance
In 2025, GSK plc's revenue was 32.67 billion, an increase of 4.11% compared to the previous year's 31.38 billion. Earnings were 5.72 billion, an increase of 121.98%.
Financial numbers in GBP Financial StatementsNews
GSK announces commencement of tender offer to acquire Nuvalent
GSK (GSK) announced that Harmony Row Acquisition Co., a direct wholly-owned subsidiary of GlaxoSmithKline, which is an indirect wholly-owned subsidiary of GSK, has commenced a tender offer to purchase...
Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)
PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) and Spero Therapeutics (Nasdaq: SPRO) today announced that the US Food and Drug Administration (FDA) has approved Utebzi, an oral antibiotic for ...
GSK, Spero Therapeutics announce FDA approval of Utebzi
GSK plc (GSK) and Spero Therapeutics (SPRO) announced that the Food and Drug Administration has approved Utebzi, an oral antibiotic for the treatment of complicated urinary tract infections including ...
US FDA approves GSK's oral antibiotic for drug-resistant UTIs
The U.S. FDA has approved GSK's oral antibiotic to treat complicated urinary tract infections, the regulator said on Wednesday, giving patients a new treatment option against drug-resistant...
Biotech IPO window is opening but big pharma M&A still sets the pace, top bankers tell CNBC
Biotech investors are far more selective than they were during the pandemic-era boom, JPMorgan's top EMEA healthcare investment bankers told CNBC. Many biotech companies are now pursuing a dual-track...
GSK announces momelotinib granted ODD from U.S. FDA, EMA
GSK (GSK) announced that momelotinib, a JAK inhibitor with a differentiated mechanism of action, has received Orphan Drug Designation, ODD, from the US Food and Drug Administration, FDA, and European…
Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion
The sudden $10.6 billion acquisition of Nuvalent NASDAQ: NUVL by GSK NYSE: GSK violently shatters a lingering mergers and acquisitions (M&A) drought across the mid-cap biotechnology sector.
Project Nashville: GSK boosts oncology rebuild with $11 billion Nuvalent deal
GSK's record $10.6 billion deal for U.S. company Nuvalent will accelerate the British drugmaker's rebuild of its cancer drug business as it seeks to fend off competition from bigger rivals AstraZenec...
Nuvalent Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Nuvalent, Inc. - NUVL
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Nuval...
After shedding its cancer business just over a decade ago, GSK's new CEO is building back with a $10.6 billion deal
After shedding its oncology business just over a decade ago, GSK is building it back with a $10.6 billion deal.
Tuesday's Morning Movers: MU Rebounds, ON PT Increases & GSK Buys NUVL
Diane King Hall discusses this morning's top moving stocks by highlighting Micron (MU) as it rallies back after Friday's sell-off. She also touches on Wells Fargo raising its ON Semiconductor's (ON) p...
Nuvalent downgraded to Hold from Buy at Stifel
Stifel downgraded Nuvalent (NUVL) to Hold from Buy with a price target of $124, down from $135, after GSK (GSK) announced that it has entered into an agreement to acquire…
GSK agrees to acquire Nuvalent for $124 per share
GSK plc (GSK) announced that it has entered an agreement to acquire Nuvalent (NUVL) a Boston-based clinical-stage biopharmaceutical company focused on creating precisely targeted oncology therapies, f...
GSK's $10.6B Nuvalent takeover fails to impress investors as shares fall: here's why
GlaxoSmithKline is making its largest oncology acquisition in years with a $10.6 billion deal for US-based cancer drug developer Nuvalent, betting that a trio of promising lung cancer therapies can he...
Cancer-Drug Stock Jumps 39% on $10.6 Billion GSK Deal. Why It's a Surprise Move.
GSK is making a tender offer for Nuvalent at $124 a share in cash, a 40% premium to where the stock traded as of Monday's close.
London's FTSE 100 falls as GSK slides after Nuvalent deal
The UK's benchmark FTSE 100 index moved lower on Tuesday, pressured by losses in healthcare giant GSK after the company announced plans to acquire shares of US-based drug developer Nuvalent in a deal ...
GSK plc Transcript: M&A announcement
The acquisition brings two late-stage, best-in-class oncology assets targeting ALK and ROS1 mutations, accelerating entry into lung cancer and supporting long-term revenue growth. Financial discipline, rapid integration, and strong physician feedback underpin confidence in clinical and commercial success.
GSK plc Slides: M&A announcement
GSK plc has posted slides in relation to its latest quarterly earnings report, which was published on June 9, 2026.
GSK plc Press release: M&A announcement
GSK plc issued a press release on June 9, 2026, disclosing material business information to investors.
GSK just announced its biggest purchase in eight years to rev up cancer portfolio it had previously wound down
U.K. pharmaceutical giant GSK on Tuesday struck a $10.6 billion deal to buy U.S.-listed biotech company Nuvalent, its biggest acquisition in eight years as it seeks to bolster the cancer portfolio it ...
GSK to Buy Nuvalent for $10.6 Billion in Oncology Push
The acquisition is set to give GSK ownership of three drug candidates for lung cancer, two of which are currently under review by the FDA for approval this year.
UK's GSK to buy US-based cancer drugmaker Nuvalent for $10.6 billion
British drugmaker GSK on Tuesday agreed to acquire U.S.-listed cancer drug developer Nuvalent for $10.6 billion.
Why GSK May Acquire Nuvalent — Report Points to $9B+ Deal Talks
GlaxoSmithKline ($GSK) is reportedly in talks to acquire cancer drugmaker Nuvalent ($NUVL). According to The Financial Times, citing people familiar with the matter, the two companies are in active di...
GSK in talks to acquire Nuvalent for more than $9 billion in biggest deal in over a decade: FT
UK pharmaceutical group GSK is in talks to acquire oncology biotech Nuvalent for more than $9 billion, according to a Financial Times report. The companies have been in discussions with the aim of fin...
GSK in talks to buy Nuvalent for $9B-$10B, FT says
GSK (GSK) is in talks to buy Nuvalent (NUVL) in a potential deal that could value the cancer drugmaker at between $9B and $10B, people familiar with the matter told…